Jiang Xiaomeng Directs Work in Natural Products Company
Release time:
2020-08-14
Jiang Xiaomeng Directs Work in Natural Products Company
News 8# July 14 Morning, Chairman of the Group Company Jiang Xiaomeng went to Tianjin Jianfeng Natural Products Company to guide the work and have exchanges and discussions with the management team and technical backbone. At the meeting of
, Liu Dan, general manager of natural products company, summarized the operation in the first half of the year and put forward the focus of work in the second half of the year. In the first half of the year, the natural products company successfully completed various work objectives, and has completed the upgrading of workshop 1, workshop 8 and storage system. the production capacity has been increased by 30%-35% , and the product structure has also been upgraded from water extraction to alcohol extraction. In the second half of the year, the company will focus on strengthening close cooperation with major universities and scientific research institutions to do a good job in product application research and innovation. Continue to increase market support for international sales, find and solve problems fundamentally; Gradually implement the construction of the second phase of the project; Continue to promote the construction of ERP office automation management system, and plan to fully implement ERP office automation system by the end of the year; continue to carry out job optimization work, improve performance appraisal and incentive systems; further strengthen quality management, actively apply for trademark patents, participate in the formulation of national standards in the industry, participate in project implementation and industrial alliances in many aspects, and do a good job in the linkage of upstream and downstream industries, thereby driving biomedicine The development of the food industry chain.
2018 is the 24th anniversary of the peak start-up 60#, and the natural product company is about to go through the course of 18 . Jiang Xiaomeng reviewed the development path of the group company and the natural product company at the meeting. Facing the severe and complex economic situation for many years, the natural product company has continuously increased its market development efforts and improved and standardized its enterprise management structure, brand influence and development speed are among the best in the extract industry. Combining the real cases of cost reduction in the peak cement industry and technological innovation in the pharmaceutical industry, Jiang Xiaomeng pointed out that both managers and decision makers must have correct strategic decisions, clear strategic goals, and precise industry positioning, and truly achieve in the industry. Quality leadership, differentiated leadership, and always maintain the core competitiveness of the enterprise can create an excellent enterprise. In the future, natural product companies should fully grasp the development direction of the extract industry, continue to increase investment in science and technology, and maintain the advantages of technological leadership and product differentiation in the industry; grasp the correct management and control model, and gradually improve various regulatory systems, management systems, and Incentive system, provide employees with an upward channel for fair competition, cultivate a loyal workforce, regulate employee management behavior guided by the system, and attract people with careers, inspire people with justice, increase customer contact with products and services, and continue to forge ahead with strong entrepreneurial passion and teamwork spirit. (Murixin)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page